NO20005032L - Treatment of parasitic diseases by inhibition of cysteine proteases by the papain superfamily - Google Patents

Treatment of parasitic diseases by inhibition of cysteine proteases by the papain superfamily

Info

Publication number
NO20005032L
NO20005032L NO20005032A NO20005032A NO20005032L NO 20005032 L NO20005032 L NO 20005032L NO 20005032 A NO20005032 A NO 20005032A NO 20005032 A NO20005032 A NO 20005032A NO 20005032 L NO20005032 L NO 20005032L
Authority
NO
Norway
Prior art keywords
inhibition
treatment
cysteine proteases
parasitic diseases
papain superfamily
Prior art date
Application number
NO20005032A
Other languages
Norwegian (no)
Other versions
NO20005032D0 (en
Inventor
Scott Kevin Thompson
Daniel Frank Veber
Thaddeus Anthony
David Graham Tew
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20005032D0 publication Critical patent/NO20005032D0/en
Publication of NO20005032L publication Critical patent/NO20005032L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20005032A 1998-04-09 2000-10-06 Treatment of parasitic diseases by inhibition of cysteine proteases by the papain superfamily NO20005032L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8122198P 1998-04-09 1998-04-09
PCT/US1999/007723 WO1999053039A1 (en) 1998-04-09 1999-04-08 Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily

Publications (2)

Publication Number Publication Date
NO20005032D0 NO20005032D0 (en) 2000-10-06
NO20005032L true NO20005032L (en) 2000-11-16

Family

ID=22162839

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005032A NO20005032L (en) 1998-04-09 2000-10-06 Treatment of parasitic diseases by inhibition of cysteine proteases by the papain superfamily

Country Status (17)

Country Link
EP (1) EP1068304A4 (en)
JP (1) JP2002511491A (en)
KR (1) KR20010042535A (en)
CN (1) CN1304447A (en)
AR (1) AR020065A1 (en)
AU (1) AU3482099A (en)
CA (1) CA2327282A1 (en)
CO (1) CO5080800A1 (en)
DZ (1) DZ2752A1 (en)
HU (1) HUP0101513A2 (en)
IL (1) IL138628A0 (en)
MA (1) MA26618A1 (en)
NO (1) NO20005032L (en)
PE (1) PE20000421A1 (en)
PL (1) PL343373A1 (en)
TR (1) TR200002940T2 (en)
WO (1) WO1999053039A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143742A (en) * 1997-12-11 2000-11-07 Fuisz Technologies Ltd Treatment for necrotizing infections
DZ2796A1 (en) * 1998-05-21 2003-12-01 Smithkline Beecham Corp New bis-aminomethyl-carbonyl compounds, process for their preparation and pharmaceutical compositions containing them.
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
NZ509172A (en) 1998-09-21 2004-02-27 Univ Florida Antimalarial agents
EP1488791A3 (en) * 1998-09-21 2005-04-06 University Of Florida Research Foundation, Inc. Antimalarial agents
CO5150165A1 (en) * 1998-11-13 2002-04-29 Smithkline Beecham Plc PROTEASE INHIBITORS: KATEPSIN K TYPE
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
WO2001034599A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
HUP0300068A2 (en) 2000-03-21 2003-05-28 Smithkline Beecham Corp Protease inhibitors, their preparation, their use and pharmaceutical compositions containing them
US6635784B2 (en) 2000-09-29 2003-10-21 Eastman Chemical Company Process for the preparation of enantiomerically-enriched cyclopropylalanine derivates
CA2429001A1 (en) * 2000-11-17 2002-11-07 Medivir Ab Cysteine protease inhibitors
NZ526913A (en) 2001-01-17 2004-12-24 Amura Therapeutics Ltd Inhibitors of cruzipain and other cysteine proteases
IL156776A0 (en) 2001-01-17 2004-02-08 Amura Therapeutics Ltd Inhibitors of cruzipain and other cysteine proteases
US7132449B2 (en) 2001-01-17 2006-11-07 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
JP2005515254A (en) 2002-01-17 2005-05-26 スミスクライン ビーチャム コーポレーション Cycloalkylketoamide derivatives useful as cathepsin K inhibitors
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US8921521B2 (en) 2003-06-18 2014-12-30 Ocera Therapeutics, Inc. Macrocyclic modulators of the Ghrelin receptor
AU2003270473A1 (en) 2003-09-09 2005-04-27 University Of Florida Desferrithiocin derivatives and their use as iron chelators
JP5202299B2 (en) 2005-04-04 2013-06-05 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド Deferithiocin polyether analogue
EP1909784A4 (en) * 2005-07-26 2010-04-21 Merck Frosst Canada Ltd INHIBITORS OF THE CYAINEINE PROTEASE OF THE PAPAINE FAMILY FOR THE TREATMENT OF PARASITIC DISEASES
AU2008229472B2 (en) 2007-03-15 2013-03-14 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues
EP2225196B1 (en) 2007-11-29 2015-01-28 Merck Canada Inc. Cysteine protease inhibitors for the treatment of parasitic diseases
WO2009087379A2 (en) 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
WO2013090750A1 (en) 2011-12-16 2013-06-20 University Of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
EP2633855A1 (en) 2012-03-01 2013-09-04 Veterinärmedizinische Universität Wien Protease inhibitors for treating Trichomonas gallinae infections
JP6838966B2 (en) 2013-11-22 2021-03-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． Desfericiosin analogs and their use
AU2016255770A1 (en) 2015-04-27 2017-11-16 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
SK56798A3 (en) * 1995-10-30 1998-12-02 Smithkline Beecham Corp Protease inhibitors, pharmaceutical composition containing them and their use
DZ2285A1 (en) * 1996-08-08 2002-12-25 Smithkline Beecham Corp Cysteine protease inhibitors.
MA26487A1 (en) * 1997-04-29 2004-12-20 Smithkline Beecham Corp PROTEASE INHIBITOR HETEROCYCLECETOHYDRAZIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Also Published As

Publication number Publication date
DZ2752A1 (en) 2003-09-15
CA2327282A1 (en) 1999-10-21
PE20000421A1 (en) 2000-05-21
EP1068304A1 (en) 2001-01-17
HUP0101513A2 (en) 2001-08-28
KR20010042535A (en) 2001-05-25
AU3482099A (en) 1999-11-01
IL138628A0 (en) 2001-10-31
CO5080800A1 (en) 2001-09-25
MA26618A1 (en) 2004-12-20
JP2002511491A (en) 2002-04-16
WO1999053039A1 (en) 1999-10-21
TR200002940T2 (en) 2001-02-21
NO20005032D0 (en) 2000-10-06
PL343373A1 (en) 2001-08-13
AR020065A1 (en) 2002-04-10
CN1304447A (en) 2001-07-18
EP1068304A4 (en) 2001-05-09

Similar Documents

Publication Publication Date Title
NO20005032D0 (en) Treatment of parasitic diseases by inhibition of cysteine proteases by the papain superfamily
ID30062A (en) SUBSTITUTIONAL BENZOPIRAN ANALOGUE FOR TREATMENT OF RADANG
NO20041882L (en) Methods for the treatment of ocular neovascular diseases.
DE60124302D1 (en) THIAZONE DERIVATIVES FOR THE TREATMENT OF PPAR-LIFE DISEASES
DE69918222D1 (en) Intranasal preparations for the treatment of sexual disorders
EE04156B1 (en) Sulfonamides for the treatment of endothelin-mediated diseases
DK0966447T3 (en) Useful small molecules for the treatment of inflammatory diseases
EE200300214A (en) Sulfonamides for the treatment of endothelin-mediated diseases
NO20012995L (en) Compounds useful for the treatment of inflammatory diseases
NO20031443D0 (en) Compounds useful for the treatment of inflammatory diseases
NO20026008L (en) Procedure for the treatment of cardiovascular diseases
NO20024775D0 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
PT1411926E (en) INTEGRINE INHIBITORS FOR THE TREATMENT OF OPHTHALMIC DISEASES
DE60218451D1 (en) 15-KETO-PROSTAGLANDINE FOR THE TREATMENT OF DRUG-INDUCED OBSTIPATION
DE50013843D1 (en) MEDICAMENT FOR THE TREATMENT OF DARMER DISEASES
EE200200632A (en) Preparations containing glucocorticoids for the treatment of bronchopulmonary disorders
NO20033804D0 (en) Carbamate compounds for the treatment of pain
ID27214A (en) TRIAZOLOPIRIDINA FOR TREATMENT OF TROMBOSIS DISORDERS
IS5951A (en) 5HT1 antidepressant for the treatment of depression
NO20024776L (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
NO20024777D0 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
DK1268482T3 (en) Pyranoindoles for the treatment of glaucoma
NO20005479L (en) sPLA2 inhibitory compounds for the treatment of disease
NO20012612L (en) Isonipecotamides for the treatment of integrin-mediated diseases
DK1200447T3 (en) Oxazinocarbazoles for the treatment of CNS diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application